AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$TLX

Smith Darren Charlton purchased $20K of TLX

Smith Darren Charlton (Group Chief Financial Officer) purchased 2,071 shares of Telix Pharmaceuticals Ltd (TLX) at $9.66 on 2026-09-07.

Original reporting
SEC EDGAR · Smith Darren Charlton
Published Sep 14, 2026, 11:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TLX
Neutral
high confidence
Mentioned
$TLX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TLXNeutralLow
01

Why it matters

The CFO's purchase modestly raises his ownership, but the transaction size is too small to affect market perception significantly.

02

Market read

Insider purchase is a routine filing with limited trading relevance.

03

What to watch

Potential upcoming FDA filing or trial data could make this purchase more meaningful.

Relevance 4/10Novelty 4/10Timing: filing released post‑market on 2026‑09‑14

Background

Form 4 disclosures provide the first public record of insider transactions.

Company-level read

Ticker impact

$TLXNeutralHigh confidence
Context

CFO Smith Darren Charlton bought 2,071 shares of Telix Pharmaceuticals for $19,997, increasing his stake to 13,992 shares.

Expected impact

Minimal short‑term price movement expected.

Evidence & confidence

Purchase size (~$20K) is negligible relative to market cap; likely no immediate trading signal.

Market effects

Sector

No broader sector impact; insider activity is isolated to Telix.

Regional

Limited to U.S. biotech investors.

Global

None

Counterpoint

What could challenge this read

Even small insider buys can precede positive news; monitor for upcoming clinical updates.

Key entities

  • Company
    Telix Pharmaceuticals Ltd

    Biopharma company listed on Nasdaq (TLX).

  • Insider
    Smith Darren Charlton

    Group Chief Financial Officer of Telix.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TLX insider trading history →

Related articles

SEP 15
$TLXHighAI 8/10

Buy, hold, sell: Domino's Pizza, Telix Pharmaceuticals, Westfarmers shares

Telix Pharmaceuticals (TLX) shares surged 10% to $17.99 after FDA approval for its brain cancer imaging drug, Pixclara, with analysts seeing 37% upside. Domino's Pizza (DMP) shares rose 1% to $19.14 despite a 11.2% revenue drop and $134.2M loss, with brokers suggesting a hold. Wesfarmers (WES) shares fell 0.5% to $72.42 after a mixed FY26 report, with most analysts recommending a sell.

fool.com.au3 min
SEP 14
$TLXHighAI 9/10

New FDA-approved brain cancer scan from Telix Pharmaceuticals (TLX) helps doctors see a key difference

Telix Pharmaceuticals (TLX) received FDA approval for Pixclara, a PET imaging drug for brain cancer (glioma). It's the first FDA-approved FET-PET imaging drug, addressing a significant unmet need in the U.S. Pixclara helps differentiate recurrent glioma from treatment-related changes, improving diagnostic accuracy. Telix is a commercial-stage radiopharmaceutical company with a portfolio of precision diagnostics and therapeutics.

stocktitan.net2 min
SEP 14
$TLXHighAI 9/10

Telix's Pixclara Wins FDA Approval For Glioma Imaging In Adults And Children

Telix Pharmaceuticals (TLX) announced FDA approval for Pixclara, a PET imaging drug for glioma. Pixclara is the first FDA-approved FET-PET imaging drug in the U.S. and is indicated for adults and pediatric patients. The approval may expand U.S. access to FET-PET imaging and support diagnosis and treatment planning. TLX stock closed at $11.29 on Friday and is up 8.95% in pre-market trading.

rttnews.com2 min
SEP 14
$TLXHighAI 9/10

FDA approves Telix’s first FET-PET imaging drug for glioma

The FDA approved Telix Pharmaceuticals' Pixclara, the first FDA-approved FET-PET imaging drug for glioma. It helps differentiate glioma progression from treatment-related changes. Telix aims to expand its precision medicine platform into brain cancer, with Pixclara targeting amino acid transporters in glioma tissue. The approval addresses a significant unmet need in brain cancer imaging.

manufacturingchemist.com3 min
SEP 14
$TLXHighAI 8/10

Lunch Wrap: Telix gets the FDA tick as oil price spoils ASX mood

The ASX 200 was flat at lunchtime on Monday. Telix Pharmaceuticals (TLX) shares rose 4% after the FDA approved its PET imaging drug for glioma brain cancer. Other movers: Cleanaway (CWY) +4%, FleetPartners (FPR) +10%, REA Group (REA) in focus after ACCC contract changes. Oil prices surged above $107 due to Middle East tensions and a likely Fed rate hike.

stockhead.com.au2 min